Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

METABOLIC FATE OF LEVO-3-HYDROXY-N-ALLYLMORPHINAN (LEVALLORPHAN)

G. J. Mannering and L. S. Schanker
Journal of Pharmacology and Experimental Therapeutics December 1958, 124 (4) 296-304;
G. J. Mannering
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. S. Schanker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The metabolic fate of levallorphan was studied in the rat, mouse, guinea pig, rabbit and dog as well as in surviving liver slices from these species.

In both in vivo and in vitro studies the formation of two metabolites of levallorphan was demonstrated. These were designated Metabolite I and Metabolite II. Crystalline Metabolite I was isolated from rat urine and from rat liver incubation mixtures. Some chemical and physical properties of this metabolite are described but its structure remains unknown. Crystalline Metabolite II, isolated from rat urine, was identified as 3-hydroxymorphinan.

Quantitative aspects of the metabolic fate of levallorphan in the rat were studied. Urine collected during the first 24 hours after a single subcutaneous injection of levallorphan tartrate (250 mg per kg) was found to contain levallorphan, Metabolite I and 3-hydroxymorphinan in the following equivalent percentages of injected drug: 5.1, 6.9 and 1.5, respectively. Levallorphan and its metabolites were found to be excreted during this period largely in conjugated form (levallorphan, 75, Metabolite I, 48, and 3-hydroxymorphinan, 80% conjugated). About 1% of the administered drug was recovered as parent compound and metabolites during the second 24-hour urine collection. Only a trace (about 1%) of levallorphan and its metabolites was found in the feces collected during the 48 hours following injection. Thus, the combined recovery of unaltered drug, Metabolite I and 3-hydroxymorphinan in the excreta leaves about 85% of the administered drug unaccounted for.

When incubated with rat liver slices, levallorphan disappears rapidly. After 3 hours of incubation only about 18% of the drug was recovered as levallorphan, Metabolite I and 3-hydroxymorphinan (3.0, 12.0 and 3.4%, respectively). Most of the drug disappears during the first hour of incubation.

Evidence is presented to show that all of the species studied form 3-hydroxymorphinan. The guinea pig and the dog do not appear to form Metabolite I. Chromatographic data indicate that Metabolite I is produced by the mouse. In addition to 3-hydroxymorphinan, the rabbit makes a metabolite which differs from Metabolite I in its chromatographic behavior.

Footnotes

    • Received July 16, 1958.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 124, Issue 4
1 Dec 1958
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
METABOLIC FATE OF LEVO-3-HYDROXY-N-ALLYLMORPHINAN (LEVALLORPHAN)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

METABOLIC FATE OF LEVO-3-HYDROXY-N-ALLYLMORPHINAN (LEVALLORPHAN)

G. J. Mannering and L. S. Schanker
Journal of Pharmacology and Experimental Therapeutics December 1, 1958, 124 (4) 296-304;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

METABOLIC FATE OF LEVO-3-HYDROXY-N-ALLYLMORPHINAN (LEVALLORPHAN)

G. J. Mannering and L. S. Schanker
Journal of Pharmacology and Experimental Therapeutics December 1, 1958, 124 (4) 296-304;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics